---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-174497"
form_type: "8-K"
ticker: "RCEL"
cik: "0001762303"
company_name: "AVITA Medical, Inc."
filed_at: "2023-06-26T23:59:59+00:00"
generated_at: "2026-06-13T17:11:38.470511+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# AVITA Medical reveals ~391K annual eligible procedures after expanded RECELL FDA approval

## Summary
- Expanded FDA indication for full-thickness skin defects opens ~391,000 annual eligible procedures.
- Traumatic wound market: ~127,000 procedures including degloving, crush, and avulsion.
- Surgical wounds (including cancer excision) total ~264,000 eligible procedures.
- Chronic wounds (DFU, VLU, pressure ulcers) account for ~128,000 annual procedures.

## SEC filing metadata
- accession: 0001193125-23-174497
- form_type: 8-K
- ticker: RCEL
- cik: 0001762303
- company_name: AVITA Medical, Inc.
- filed_at: 2023-06-26T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1762303/000119312523174497/0001193125-23-174497-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1762303/000119312523174497/d521007d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-174497
- JSON: https://secwatch.observer/filing/0001193125-23-174497.json
- Plain text: https://secwatch.observer/filing/0001193125-23-174497.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.